Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Anti-obesity drug class going extinct

Executive Summary

In an unsurprising move, Pfizer calls it quits for its experimental cannabinoid receptor antagonist, CP-945,598, saying that despite an independent review that deemed the compound has the potential to be a safe and effective treatment for weight management, it will discontinue the development program based on changing regulatory perspectives on the risk/benefit profile of the CB-1 class - also, obesity is no longer part of Pfizer's R&D strategy (1"The Pink Sheet," Oct. 6, 2008, p. 20). Sanofi-Aventis also announced it is ceasing development activity for its CB-1 antagonist rimonabant; the firm pulled the drug in Europe, where it was marketed as Acomplia, after an EMEA committee concluded the psychiatric risks outweigh the benefits (2"The Pink Sheet" DAILY, Oct. 23, 2008). Earlier in October, Merck dropped development of taranabant, after effective doses turned up psychiatric side effects and didn't work as well in lower doses (3"The Pink Sheet," Oct. 6, 2008, p. 22)

You may also be interested in...

Metabolic, Diabetes Landscape “Fertile Ground” For Partnerships

Pharma should look at market that “grows larger with every meal,” says Healogix CEO Kaplan.

Sanofi’s Rimonabant Off The European Market; CHMP Finds Risk Management Plan Does Not Adequately Address Depression

Acomplia use doubles risk of psychiatric disorders in overweight patients, European review finds.

Taranabant Loss No Surprise For Obesity Field, But Shock To Merck’s Pipeline

Merck's widely expected decision to drop its Phase III obesity candidate taranabant places further doubt on the tainted cannabinoid-1 receptor antagonist class, but it also places doubt on Merck's near-term pipeline

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts